Colgate-Palmolive Company

(New York Stock Exchange)
Back to all articles
Bullish +65

Prediction: Colgate-Palmolive Will Jump 20% This Year

AI-generated analysis

πŸ“ˆ Analysts predict a 20% price jump for Colgate-Palmolive this year with a specific target of $103.17.

πŸ“Š Q1 2026 earnings beat adjusted EPS expectations, extending a four-quarter streak of positive surprises.

πŸ’° Revenue grew 8.4% YoY to $5.324 billion, driven by strong double-digit growth in Latin America and Europe.

πŸš€ Free cash flow jumped 27.94% to $609 million, demonstrating improved operational efficiency.

πŸ’΅ The company raised its dividend to $0.53 per quarter for the 63rd consecutive annual increase.

πŸ›‘οΈ A restructuring program targets $200-$300 million in annual pretax savings to fund advertising and margin recovery.

πŸ“‰ Tariff pressures have forced management to revise 2026 GAAP gross margin guidance from up to down.

⚠️ Colgate recorded a $919 million goodwill impairment for its Filorga business due to China weakness.

πŸ“ˆ Emerging markets organic sales grew 6.2%, offsetting a decline in North American volumes.

🎯 The stock trades at a forward P/E of 23, which analysts argue is more realistic than the trailing multiple.

Bullish Signals
  • Colgate-Palmolive reported adjusted EPS of $0.97, beating the consensus estimate of $0.9445 and extending a four-quarter beat streak.
  • Revenue grew 8.4% year-over-year to $5.324 billion, with Latin America up 14.8% and Europe up 11.9%.
  • Free cash flow surged 27.94% to $609 million in the first quarter of 2026.
  • The company increased its quarterly dividend to $0.53, marking the 63rd consecutive annual increase.
  • Organic sales growth is accelerating from 0.4% in Q3 2025 to 2.9% in Q1 2026.
  • Emerging markets organic sales grew 6.2%, providing a strong counterbalance to North American declines.
  • The expanded SGPP restructuring program targets $200-$300 million in annual pretax savings.
  • Operating cash flow grew 24.5% in Q1, indicating strong underlying business health.
  • The stock has gained 12.04% year-to-date and sits only 3% below its 52-week high.
Risk Factors
  • Management revised 2026 GAAP gross margin guidance from up to down due to evolving tariff pressures.
  • North America organic sales declined 1.8% in Q1 and 2.2% overall, indicating regional weakness.
  • The Filorga skin health business triggered a $919 million goodwill impairment in Q4 2025 tied to China weakness.
  • A trailing P/E of 34 leaves little room for execution slippage despite the one-time charge distortion.
  • Key risks include tariff escalation broadening beyond consumer staples and further deterioration in North America volumes.
Full Analysis
24/7 Wall St. predicts Colgate-Palmolive (NYSE:CL) shares could jump 20% this year, setting a price target of $103.17 with a buy rating and 90% confidence. The stock has already gained 12.04% year-to-date as investors favor its low beta and defensive characteristics amidst macroeconomic uncertainty. With shares trading at $87.44, the analysis suggests significant upside potential driven by accelerating organic sales growth and a robust dividend history. The company recently reported strong Q1 2026 earnings, beating adjusted EPS expectations of $0.97 versus consensus and extending a four-quarter beat streak. Revenue grew 8.4% year-over-year to $5.324 billion, with standout performance in Latin America (up 14.8%) and Europe (up 11.9%), while free cash flow surged 27.94% to $609 million. The dividend was increased to $0.53 per quarter, marking the 63rd consecutive annual increase. The bullish case relies on three main pillars: accelerating organic sales growth in emerging markets, a restructuring program targeting $200-$300 million in annual pretax savings, and a resilient balance sheet. However, risks include ongoing tariff pressures that have forced management to revise gross margin guidance downward and a recent $919 million goodwill impairment related to the Filorga skin health business due to weakness in China. Analysts note that while the trailing P/E of 34 appears high, it is distorted by the one-time Filorga charge, making the forward P/E of 23 more relevant. The model projects a bear-case floor of $92.10, highlighting the downside protection provided by the stock's low volatility and consistent dividend payments. Key risks to monitor include further tariff escalation and volume deterioration in North America.